Infections of different etiologies, neurotropic or not, have been associated with acute and long-term neurological consequences (Jurgens et al., 2012; Hosseini et al., 2018; Barbosa-Silva et al., 2021). These consequences involve cognitive decline and behavioral disorders such as depression and anxiety. The main cause of these sequelae is an inflammatory condition in the central nervous system (CNS) characterized by an increase in pro-inflammatory mediators secreted by glial cells, such as microglia and astrocytes (Dantzer et al., 2008; Wendeln et al., 2018).

Microglia, which has long been described as a resident immune cell in the CNS, is currently considered an essential and versatile cell, having well-defined roles in maintaining neuronal networks, supporting synaptic plasticity, repairing injuries, and participating in the inflammatory process (Heneka et al., 2015). Microglial cells express pattern recognition receptors (PRRs) that recognize molecules known as pathogen-associated molecular pattern molecules (PAMP) and damage-associated molecular patterns (DAMPs). During infection, irrespective of whether the pathogen can invade the CNS, the microglia will respond quickly by altering its state. Once confronted with stimuli, microglia induce and modulate a broad spectrum of molecular and cellular responses in an attempt to eradicate the pathogen (Heneka et al., 2014; Widmann and Heneka, 2014).

Evidence suggests that changes in microglial morphology, functionality, and subsequently priming of microglial cells may be involved in the development of neurodegenerative diseases (Perry et al., 2007; Püntener et al., 2012; Barbosa-Silva et al., 2018; Haley et al., 2019; De Sousa et al., 2021). In this review, we will focus on microglial changes resulting from infectious diseases inducing microglial priming and how this phenomenon could be associated with the development of neurogenerative diseases.

Microglia are currently defined as yolk sac-derived, long-living cells that persist into adulthood and self-renew within the CNS parenchyma without any contribution from bone marrow-derived cells in the steady-state (Paolicelli et al., 2022). Microglial cells are heterogeneous and vary according to the brain region, displaying distinct intrinsic properties and performing distinct physiological functions. They can vary with age, sex, and pathology-specific (or stimulus-specific) (Davalos et al., 2005; Hines et al., 2009; Lenz and McCarthy, 2015; De et al., 2018; Plescher et al., 2018; Stratoulias et al., 2019; Villa et al., 2019). Due to their myeloid origin, microglia have long been described as CNS macrophages. However, other populations of CNS macrophages can be found, such as perivascular macrophages, meningeal macrophages, circumventricular organ macrophages, and choroid plexus macrophages (Kierdorf et al., 2019). Although microglia and macrophages share common characteristics, such as a strong and variable capacity to respond to inflammatory conditions, they differ in ontogeny, number, function, and mainly in location (Kierdorf et al., 2019).

Microglia are anything but static, as they are extremely sensitive to changes in their environment (Paolicelli et al., 2022). A broader spectrum of different microglia states is associated with different stimuli and roles in homeostasis and disease (Streit, 2002; Herz et al., 2017; Tay et al., 2017; Muzio et al., 2021). Under homeostatic conditions, microglia present a homeostatic state that participates in several active functions within the CNS, including continuous motility and maintenance of CNS functions. Their functions evolve in response to their specific location and reciprocal interactions with nearby cells and structures and play essential roles, such as neurotrophic factor production, synaptic pruning, and immunological surveillance (Nimmerjahn et al., 2005; Stratoulias et al., 2019; Paolicelli et al., 2022). Their morphology, ultrastructure, and molecular profile are all dynamic and plastic, resulting in a wide range of cell states (Paolicelli et al., 2022).

Hippocampus neurogenic niches and the production of new neurons also depend on roles played by homeostatic microglial cells (Arnò et al., 2014). Additionally, these cells are necessary for the elimination of amyloid β (Aβ) peptide and abnormal tau protein, protecting the CNS from the development of neurodegenerative diseases (Bellucci et al., 2004; Hickman et al., 2008; Meyer-Luehmann et al., 2008; Sasaki et al., 2008; Zilka et al., 2009; Nalivaeva et al., 2012; Ries and Sastre, 2016; Perea et al., 2018a, 2020; Španić et al., 2019; Jin et al., 2021; d’Errico et al., 2022). The morphology of the homeostatic microglia presents cellular processes with high motility, which help to detect the brain parenchyma, and interact with other cells, such as neurons and astrocytes, and blood vessels (Nimmerjahn et al., 2005; Hickman et al., 2018; Stratoulias et al., 2019). Furthermore, these states are characterized by constitutive expression of macrophage antigens such as complement receptor 3 (CD18/CD11b) and low expression of the major histocompatibility complex (MHC) II (Ehlers, 2000; Frank et al., 2006; Colton and Wilcock, 2010; Czirr et al., 2017).

Conversely, during CNS injuries, such as infectious and neurodegenerative diseases, microglial cells present a complex response, transitioning from a homeostatic state and assuming a pro-inflammatory state to solve the infection/injury. Among the states that can be assumed by microglia is an anti-inflammatory state, whose function is to promote tissue remodeling and repair although, in several cases, microglia assume a pro-inflammatory state. It is not easy to accurately define these states because the responses are highly heterogeneous and microenvironment dependent. Even similar stimuli may elicit distinct microglia responses, constructing a different spectrum of reactivities (Scheffel et al., 2012; Kamigaki et al., 2016; Friedman et al., 2018; Furube et al., 2018; Stratoulias et al., 2019). Despite differences, it is possible to define characteristics and roles associated with a pro-inflammatory microglial state that characterizes inflammatory conditions. The acute inflammatory response leads to functional and morphological changes in microglial cells, including upregulation of some molecules, such as CD11b, Intercellular adhesion molecule-1 (ICAM-1), P-selectin, major histocompatibility complex II (MHC II), CD80 (T-cell costimulatory molecules B7–1), CD86 (T-cell costimulatory molecules B7–2), and CD40 [a member of the tumor necrosis factor (TNF) receptor; Colton and Wilcock, 2010; Yeini et al., 2021]. Pro-inflammatory microglia cells present a branch architecture with thicker processes and in some cases a complete amoeboid morphology, characterized by a round cell body and few and short processes, similar to a macrophage (Davis et al., 1994; Fernández-Arjona et al., 2017; Savage et al., 2019; Franco-Bocanegra et al., 2021). Furthermore, they increase the production and release of mediators, including reactive oxygen species (ROS), interleukin (IL)-1β, IL-6, TNFα, nitric oxide (NO₂), acute phase proteins such as pentraxin-3 involved in microglial phagocytic activity and indoleamine 2,3 dioxygenase (IDO) activity (Dantzer et al., 2008; Jeon et al., 2010; Heneka et al., 2015). This microglial state presents higher rates of phagocytosis, especially near damaged neurons and neurotoxic aggregates, both in vitro and in vivo (Neher et al., 2011; Rajbhandari et al., 2014), which is considered to have a protective role against inflammatory microglia. However, although lipopolysaccharide (LPS) and neurotoxic aggregates are able to promote phagocytosis (Herber et al., 2004), chronic stimulation of these cells decreases their phagocytic capacity, causing a reduction in aggregate clearance, which may contribute to improving neurodegenerative processes (Mawuenyega et al., 2010; Krabbe et al., 2013; Hong et al., 2016). Furthermore, pro-inflammatory microglia are described as highly pro-oxidant (García-revilla et al., 2019), and could be considered as a neurotoxic phenomenon.

Microglia orchestrate a “defense and repair” mechanism once faced with a challenge. This inflammatory response per se is not an adverse process but is necessary to restore tissue homeostasis. Inflammatory processes work under tight control to ensure that microglia will be regulated toward a pro-resolutive state once their task has been completed. Considered a double-edged sword, this acute inflammatory response is a necessary mechanism against pathogens and damaged cells. However, if this response is prolonged, it may exacerbate neurodegeneration by placing pro-inflammatory microglial cells as relevant players acting as a hallmark of neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (Shabab et al., 2017; Hickman et al., 2018).

The concept of trained immunity, described mainly in peripheral innate immune cells, may explain microglial priming. It refers to the ability of these cells to develop and display memory for inflammatory and infectious challenges (Chapoval et al., 1998; Schroder et al., 2006; Perry and Holmes, 2014). Microglial priming is a long-lasting memory change of microglia, which occurs mainly after exposure of cells to inflammatory stimuli, such as LPS, inflammatory mediators, misfolded proteins, and neuronal fragments (Perry and Holmes, 2014; Haley et al., 2019). Primed microglia are more sensitive to potentially milder stimuli, where a second stimulus/hit leads to an exacerbated response compared to the first stimulus/hit. Basically, priming results in increased immune reactivity to secondary insult and also makes microglia more resistant to negative/regulatory feedback (Perry and Teeling, 2013; Perry and Holmes, 2014). Exaggerated inflammatory responses caused by microglia may impair homeostatic functions and lead to CNS damage, including impaired synaptic plasticity and neurodegeneration (Boje and Arora, 1992; Mizuno, 2015; Haruwaka et al., 2019; Therajaran et al., 2020; Vainchtein and Molofsky, 2020).

The idea of macrophage priming is well established in vitro. Treating these cells with interferon (IFN)-γ prior to a challenge with a Toll-like receptor (TLR) agonist enhances the response to the TLR agonist, probably due to activation of phosphoinositide 3-kinase (PI3K) and/or nuclear factor-kB (NF-kB; Schroder et al., 2006). In vivo studies show that preexposure to colony stimulating factor (CSF)-1 (intravenously and intraperitoneally) increases serum levels of IL-6 and TNF in response to a subsequent LPS challenge. In addition, isolated cells, such as peripheral blood leukocytes, spleen cells, and resident peritoneal cells from CSF-1-primed mice injected with LPS, release IL-6 constitutively (Chapoval et al., 1998). This process is accompanied by the long-term reprogramming of intracellular signaling and metabolic pathways and is fixed epigenetically (Lajqi et al., 2019).

The first evidence of microglial priming supported the idea that patients with chronic neurodegenerative diseases, such as Alzheimer’s disease, when affected by peripheral infections and systemic inflammation had greater consequences compared to healthy elderly individuals, such as greater chances of hospitalization, exacerbation of symptoms, and progression of neurodegeneration (Perry et al., 2007). Tahira et al. (2021) recently showed that Alzheimer’s disease is a risk factor for the severe form of COVID-19, also increasing the risk of mortality from coronavirus infection, regardless of age. Furthermore, MHC II is considered a marker of microglial priming in conditions such as aging and neurodegenerative diseases and is upregulated in the postmortem brain of patients with COVID-19 (Perry and Holmes, 2014; Matschke et al., 2020). Evidence for microglial priming has been shown in several models of neurodegenerative disorders, such as in transgenic mice with Alzheimer’s disease, in which LPS injection presented an increase in the inflammatory response (Sly et al., 2001). Furthermore, in a microglial priming model using a single intraperitoneal dose of methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and 4 days after the animals received a subtoxic dose of LPS, the animals showed an amplified inflammatory response, nigrostriatal dopaminergic degeneration, and an increase in protein expression levels of the components of the NLRP3 inflammasome and of NF-κB activity compared to animals that received only MPTP or LPS (Leem et al., 2021). Moreover, IL-1β injection intensifies cell degeneration in the substantia nigra and motor symptoms in a Parkinson’s disease model (Godoy et al., 2008). Thus, the additional stimulus in a microglial population due to a peripheral infection can aggravate inflammation and consequently cause greater harm to the patient. These findings demonstrate that microglial priming can occur in a pre-existing inflammation of the CNS, caused by a neurodegenerative disease, with a posterior peripheral infection. However, it is possible to suggest that this process is multimodal and therefore may be associated with the infectious process bilaterally.

After the 1918 influenza pandemic, epidemiological studies associated the outbreak of Encephalitis lethargica and Post-encephalitic Parkinsonism with the H1N1 pandemic (Ravenholt and Foege, 1982). A direct association between influenza and encephalitis lethargica was first reported in 1974, when viral antigens were found, using immunofluorescent staining, in the brain specimens of patients who had been diagnosed with encephalitis lethargica and Parkinsonism (Gamboa et al., 1974). However, these correlations were never proven and remain controversial (Mattock et al., 1988; Casals et al., 1998; Oxford, 2000; Henry et al., 2010; Vilensky et al., 2010; De Chiara et al., 2012; Dourmashkin et al., 2012).

Still, viral infections might provide the first stimulus that may lead to the subsequent development of neurodegenerative diseases (Estupinan et al., 2013). H1N1-infected mice given MPTP to induce Parkinson’s disease, present a decrease in the number of dopaminergic neurons in the substantia nigra pars compacta (SNpc) when compared to mice that were not previously infected with H1N1. Furthermore, animals previously vaccinated against H1N1 or treated with the antiviral drug oseltamivir carboxylate before MPTP exposure had similar numbers of dopaminergic neurons in the SNpc as control animals. These findings suggested that H1N1 infection alone was not able to cause Parkinsonism; however, it was responsible for priming the immune response in the brain, which could lead to Parkinson’s disease when another stimulus was added (Sadasivan et al., 2017). Thus, influenza led to the activation of the innate immune system in the brain, resulting in a later exacerbated response to the effects of a known Parkinsonian agent, MPTP.

Influenza infection and neurodegenerative disorders were also reported in studies by Ogata et al. (1997) where rodents exposed to the Japanese encephalitis virus presented neuronal loss, gliosis, and a decrease in the number of dopaminergic TH-positive neurons in the substantia nigra, all hallmarks of Parkinson’s disease. Infections with the neurotropic strain H5N1 in mice lead to neurodegeneration in the substantia nigra, especially in dopaminergic neurons (Jang et al., 2012), and even non-neurotropic strains, such as H1N1, also lead to brain inflammation and microgliosis in the hippocampus (Jurgens et al., 2012; Hosseini et al., 2018), despite the absence of virus in the brain (Sadasivan et al., 2015), indicating that both neurotropic and non-neurotropic influenza can lead to neurodegeneration.

The connection between viral infections and neurodegenerative disease is not limited to influenza; other viral infections may also result in neurodegeneration. Human herpes virus-6 (HHV-6) expression (mRNA and protein), was detected in a periventricular multiple sclerosis lesion, specifically in oligodendrocytes (Leibovitch and Jacobson, 2014). Furthermore, HHV-6 is associated with the development of Alzheimer’s disease. Readhead et al. (2018) using a multiscale analysis in postmortem brain tissue from patients with Alzheimer’s disease, observed a relationship between the viral abundance of HHV-6 and 7 and genes related to amyloid precursor protein, an important feature of Alzheimer’s disease. In addition, recent studies have shown the relationship between Epstein-Barr infection (EBV) and multiple sclerosis (Bjornevik et al., 2022).

Viral infections are associated with neurodegeneration hallmarks. Parasite infections have also been associated with the development of neurodegenerative disorders. Mice infected with Toxoplasma gondii associated with the administration of subdoses of Aβ peptide presented significant impairments in learning and memory functions and increased IL-1β, TNF-α, IFN-γ, and inducible nitric oxide synthase (iNOS) mRNA levels, similar to the Alzheimer’s disease group, which received high doses of Aβ but were not infected (Mahmoudvand et al., 2016). In recent decades, many studies have investigated the mechanisms related to long-term cognitive and behavioral sequelae resulting from malaria infection. Microglial changes are observed in experimental models of malaria and in postmortem brains of patients with malaria (Janota and Doshi, 1979; Schluesener et al., 1998; Talavera-López et al., 2018). Microglial human cells phagocytize extracellular vesicles derived from red blood cells infected with Plasmodium falciparum, the main parasite that causes cerebral malaria in humans, resulting in morphological changes including cytoplasmic granulations, formation of numerous pseudopods, process retraction and cell body swelling (Mbagwu et al., 2020). In an experimental model of cerebral malaria, magnetic resonance imaging revealed the time course of rupture of the BBB, an event essential for the development of this cerebral malaria, beginning in the olfactory bulb and spreading along the rostral migratory flow accompanied by a specific route of microglial changes related to the pro-inflammatory state (Hoffmann et al., 2016). In experimental malaria models, cognitive dysfunction has been correlated with the pro-inflammatory microglial state (Desruisseaux et al., 2008; Guha et al., 2014; Lacerda-Queiroz et al., 2015; Souza et al., 2018; Andoh and Gyan, 2021). Microglial transcriptomic analysis revealed that in the acute phase of experimental malaria infection, where the brain is already severely affected, there is increased expression of genes related to immune responses (Capuccini et al., 2016; Talavera-López et al., 2018). BV-2 cells, a microglial cell line, stimulated with hemozoin, a molecule resulting from plasmodium metabolism, induced an increase in the production of TNFα, IL-6, IL-1β, and NO (Velagapudi et al., 2019). Furthermore, minocycline treatment, a drug that has been described to regulate microglial functions, including inhibition of the pro-inflammatory state and restoring phagocytic functions, prevented the development of cerebral malaria and conferred neuroprotection in infected mice (Markovic et al., 2011; Kobayashi et al., 2013; Hu et al., 2014; Apoorv and Babu, 2017; Bassett et al., 2021; Paolicelli et al., 2022). Taking into account the concept of microglial priming, more studies are needed to evaluate the involvement of microglia in the pathogenesis and development of neurodegenerative diseases in malaria survivor patients, as this disease leaves long-term neurological sequelae.

Bacterial infections can also promote neural damage and changes in the microglial response. Mice previously challenged with Salmonella typhimurium presented a robust inflammatory response to low doses of injection of LPS into the brain, but in previously uninfected mice these low doses did not evoke or evoke a small inflammatory response (Püntener et al., 2012). Furthermore, LPS injection promoted axonal injury in an experimental model of multiple sclerosis, a key contributor to the progression of disability in multiple sclerosis (Moreno et al., 2011). The LPS challenge was performed in the reemission phase of the disease, causing systemic inflammation that correlates with pro-inflammatory microglia and axonal damage, suggesting that systemic infections can contribute to the aggravation of neurodegenerative diseases. Porphyromonas gingivalis infection in the transgenic mouse model of Alzheimer’s disease (APP-Tg) increased the deposition of Aβ and the levels of inflammatory cytokines in the brain. They also observed that microglial cell cultures that were previously exposed to Aβ oligomers and then exposed to Porphyromonas gingivalis endotoxin presented an increase in TNF-α and IL-1β production (Ishida et al., 2017). Septic mice have been reported to be more susceptible to Aβ oligomers, and this could be due to a long-lasting trained innate immunological memory (De Sousa et al., 2021). Microglial cells from surviving septic mice appear to be more responsive and are more prone to shift to a pro-inflammatory profile, when exposed to smaller amounts of Aβ when compared to control mice, leading to an increase in synapses phagocytosis in the hippocampus. Pharmacological blockade of brain phagocytic cells or microglial depletion, using minocycline and CSF-1 receptor inhibitor (PLX3397), respectively, prevented AβO-induced cognitive dysfunction in surviving septic mice (De Sousa et al., 2021). Furthermore, using a transgenic animal model for Alzheimer’s disease (APP/PS1–21 transgenic mouse) that underwent a septic event through cecal ligation and puncture (CLP) surgery, the animals presented increased fibrillar amyloid plaque formation in the hippocampus, in addition to the slight changes found in the microglia (Basak et al., 2021). Together, these results suggest that sepsis could be a potential factor in increasing dementia and may contribute to the mechanisms involved in exacerbated amyloid plaque deposition.

Furthermore, some evidence suggests that inflammation resulting from an uncontrolled microglial response may precede the development of diseases known as tauopathies. The Tau protein is a soluble protein associated with microtubules that is expressed primarily by neurons located in the cytoplasm and axons (Gorath et al., 2001; Wang et al., 2013). These proteins have been shown to be involved in the pathology of several neurodegenerative diseases, including Alzheimer’s disease. Aggregated and hyperphosphorylated tau proteins form the core of neurofibrillary tangles, which are one of the pathological hallmarks of Alzheimer’s disease. The mechanisms involved in these pathologies are still not completely understood, but exosomes may be an important link between tau propagation and the pro-inflammatory microglial state (Gao et al., 2018; Španić et al., 2019). Reducing the number of microglial cells and inhibiting exosome synthesis reduces the spread of tau proteins (Asai et al., 2015); thus, serum levels of tau protein are useful to support findings of acute neuronal damage, including acute ischemic stroke, traumatic brain injury, intracranial hemorrhage, epilepsy, and cardiac arrest (Bitsch et al., 2002; Palmio et al., 2009; Hu et al., 2012; Randall et al., 2013; Mattsson et al., 2017; Tang et al., 2019; Nakada et al., 2020). In patients with sepsis, serum tau protein levels were significantly higher in the group that did not survive compared to the surviving individuals; therefore, it may be useful as a mortality predictor in patients with severe sepsis (Zhao et al., 2019). Furthermore, rats that received a single dose of LPS showed hippocampal deposition of intracellular phosphorylated tau protein (Kirk et al., 2019). More studies are needed to understand the association of tau protein with neurodegenerative diseases; however, these findings may help explain the higher rate of dementia observed in longitudinal studies of septic survivors (Chou et al., 2017).

Brain inflammation can occur as a result of direct injury to the CNS, such as infection, trauma, or neurodegenerative diseases, but also may be a consequence of systemic inflammation caused by infections (Young, 2013) of which microglial cells are key players. There are several routes of communication between the periphery and the brain, but we can highlight three major pathways. First, afferent nerves, such as vagal nerves in adnominal infections and trigeminal nerves in orolingual infections (Bluthé et al., 1996; Ek et al., 1998). Second, inflammatory mediators present in the circulation communicate directly with circumventricular organs, which do not have an intact BBB; then, this signaling is spread by microglia into the brain parenchyma (Quan et al., 1998). Third, pro-inflammatory mediators or microbial products can interact directly with cells in the brain endothelium, signaling directly through the BBB and with perivascular macrophages (Vitkovic et al., 2000). All these routes will allow the brain to recognize the peripheral inflammatory state and then glial cells, mainly microglia, will respond by releasing pro-inflammatory molecules.

Once in the brain, cytokines lead to several changes in the states of glial cells (microglia and astrocytes), neurotoxic mechanisms, and modulate neurotransmitter metabolism (Heneka et al., 2015; DiSabato et al., 2016). This inflammatory scenario plays an important role in the progression of neurodegenerative diseases. Seminal articles in this area described highly reactive microglia, evaluated by the expression of the human leukocyte antigen DR isotype (HLA-DR) and other immune cells, such as T cells, in the brains of patients with Alzheimer’s and Parkinson’s disease (McGeer et al., 1987, 1988; Itagaki et al., 1988). These studies laid the foundation for considering brain inflammation as a potential factor involved in the onset and/or development of these pathologies.

Neurodegenerative diseases are not easy to diagnose due to the heterogeneity of pathological biomarkers, most are only identifiable by postmortem examination. But there are some hallmarks associated with loss of neurons and synapses, gliosis, and vascular abnormalities in specific regions of the brain, and in inflammation (Villoslada et al., 2020). The persistent inflammatory state found in neurodegenerative diseases is detrimental to microglia and other glial cells, as this continuous state increases ROS and NO production. In a vicious cycle, inflammation eventually can lead to neurodegeneration resulting in protein aggregation, dysfunctional cells, and neuronal death (Arcuri et al., 2017; Marttinen et al., 2018). In Parkinson’s disease, pro-inflammatory microglia phagocytose injured neurons and induce the release of inflammatory mediators, including ROS, NO, and IL-6; These mediators will contribute to astrogliosis that exacerbates inflammation and increases the phagocytosis of neuronal debris mediated by microglia cells. Furthermore, the aggregation of alpha-synuclein itself accelerates this process by inducing IL-1β releasing via TLR signaling (Hickman et al., 2018; Marttinen et al., 2018; Subhramanyam et al., 2019). A similar process related to Aβ aggregation also occurs in Alzheimer’s disease (Marttinen et al., 2018). This evidence suggests that microglia cells contribute to the initiation and amplification of the neurodegeneration process.

The common point between infectious diseases and neurodegenerative disorders appears to be the inflammatory process, which involves a microglial response. Experimental evidence is still preliminary; however, it allows us to hypothesize that brain inflammation caused by peripheral infections—or repeated exposure to infections throughout life—may be/act as an initial microglial priming event, first hit, and subsequent neuroinflammatory stimuli, second hit, may promote an exacerbated microglial pro-inflammatory response, causing a series of biological events related to the development of neurodegenerative diseases (Figure 1). Finally, infections that occur in early life also highlight the role of microglial priming. Infections at this period of life are described leaving long-term sequelae, such as cognitive deficits, in adulthood (Bilbo et al., 2005; Ratnayake et al., 2013; Li et al., 2014; Han et al., 2017; Osborne et al., 2017; Granja et al., 2021). Experimental models show that microglial priming alone does not lead to these deficits, as studies emphasize the importance of a second stimulus/hit for the development of cognitive sequelae (Bilbo et al., 2005; Bilbo, 2010; Li et al., 2014; Osborne et al., 2017). In addition, the role of infections in early life and their role as risk factors for the development of neurodegenerative diseases have been discussed (Miller and O’Callaghan, 2008).

The impact of systemic inflammation on the development of neurodegenerative diseases has been extensively explored. LPS administration, in different experimental models, has been described to increase the deposition of Aβ protein, cognitive deficits, phosphorylated tau protein, and decrease the level of dopaminergic neurons that are hallmarks of Alzheimer’s and Parkinson’s disease, respectively (Lee et al., 2008; Kahn et al., 2012; Kiyofuji et al., 2015; Kirk et al., 2019; Tejera et al., 2019; Wang et al., 2020). Not only is LPS injection related to the development of neurodegenerative diseases, systemic delivery of TNF-α leads to disease behavior, cognitive deficit, increase in tau expression, and IBA-1 staining in the mouse hippocampus (Hennessy et al., 2017). Furthermore, systemic inflammatory challenge in the prenatal phase, at the end of gestation, with viral mimic, polyriboinosinic-polyribocytidyl acid (PolyI:C) predisposes healthy mice to develop a pathology similar to Alzheimer’s disease (Krstic et al., 2012). Animals showed high levels of IL-1β, IL-1α, and IL-6 in plasma and the brain in the early stages and during aging (3–15 months of life). Microglial cells with altered activity were observed by immunostaining with CD68, a marker of phagocytosis and antigen presentation, in the CA1 region of the hippocampus (Krstic et al., 2012). Furthermore, prenatal exposure to PolyI:C resulted in a significant age-dependent increase in the amount of amyloid precursor protein (APP) in the hippocampus and altered Tau phosphorylation and significant impairment of working memory in old-age mice, evaluated by the Y-maze test (Krstic et al., 2012). Although a single prenatal immune challenge was sufficient to generate a chronic inflammatory state of the CNS in animals and increase the vulnerability of the brain to the development of neurological diseases, the study even showed that a second immune challenge in adulthood exacerbated this state, including increased APP deposition, Tau protein aggregation, and microglial profile modification (Krstic et al., 2012). These results show that it is possible that early or repeated exposure to inflammation is an initiating event for microglia that may lead to long-term sequelae, including an increased predisposition to the development of neurodegenerative diseases.

Microglial priming is directly related to the exacerbation of the inflammatory response and, consequently, to increased brain inflammation and subsequent damage. Mice challenged with LPS 12 weeks after inoculation with ME7 prion, a neurodegenerative experimental model used to study brain inflammation (Chouhan et al., 2017), demonstrated exacerbated neuronal death, behavioral deficits, increased IL-1β, TNF-α, and IFN-β levels in the brain, and increased microglial IL-1β (Cunningham et al., 2009; Murray et al., 2011). Priming BV-2 microglial cells with IFN-γ substantially increased the production of ROS after microglial stimulation with ATP (Spencer et al., 2016). IFNγ-induced priming by promoting upregulation of the NADPH oxidase NOX2 subunit and reducing intracellular glutathione levels (Spencer et al., 2016). Oxidative stress and subsequently mitochondrial damage are one of the main causes of neuronal damage in several brain disorders including Alzheimer’s and Parkinson’s disease and are mainly caused by pro-inflammatory microglia due to excessive ROS production mediated by NADPH oxidase (Simpson and Oliver, 2020). Considering that infectious diseases lead to the synthesis of several pro-inflammatory cytokines such as IFN-γ, mitochondrial oxidative damage via ROS-induced by pro-inflammatory cytokines could be one of the mechanisms by which infectious diseases lead to neurodegenerative conditions (Brown et al., 1999; Romero et al., 2010; Sturge and Yarovinsky, 2014; Kyuwa and Sugiura, 2020).

Thus, repeated infectious processes can act as a second hit and trigger a response in the primed microglia. However, it is important to emphasize that the aging process itself can be considered a second hit. It was shown that early postnatal infection of rats with LPS combined with the aging process resulted in less successful cognitive aging in these animals (Bilbo, 2010). Aging is a risk factor for the development of many neurodegenerative diseases because the natural aging process includes functional and structural changes within the brain (Bennett et al., 1996; Reeve et al., 2014; Maniega et al., 2015; Chen et al., 2020). Among these changes is immune system dysfunction, which generates a low-grade chronic pro-inflammatory condition called inflammageing (Franceschi et al., 2018). Furthermore, aging-related microglia in the aged brain and the pro-inflammatory microglial state show decreased motility, metabolic and immune changes, such as increased constitutive production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, and IL-6; Sierra et al., 2007; Hefendehl et al., 2014; Marschallinger et al., 2020; Schiess et al., 2020; Shaerzadeh et al., 2020). RNAseq analysis of microglia from elderly mice showed that the pathway of genes related to phagosome maturation and NO and ROS production was dysregulated, producing an impairment of essential microglial functions (Marschallinger et al., 2020). Although aging is not a disease, it can lead to nonbeneficial changes in the physiological role of microglia and may be a microglial priming factor. Therefore, the dysfunctional role of microglia and the chronic inflammatory microenvironment may be associated with neurodegeneration. Peripheral LPS injection into aged mice enhanced cortical microglial response and increased IL-1β and IDO mRNA levels in microglia isolated from aged mice compared to adult mice (Wynne et al., 2009). These findings suggest that an inflammatory condition, caused by aging, before a second stimulus contributes to exacerbating a subsequent response.

CX3CL1-CX3CR1 signaling is essential for microglia-neuron communication and may play an important role in the progression of neurodegenerative diseases. In the hippocampus of elderly rats, CX3CL1 expression is reduced and this is correlated with changes in microglia, including increased expression of CD40 mRNA and MHC II and IL-1β expression (Lyons et al., 2009). In adult mice, microglia can restore CX3CR1 levels 24 h after LPS challenge, whereas CX3CR1 was still significantly reduced in the microglia of aged mice (Wynne et al., 2010). In Alzheimer’s disease, CX3CL1 expression is reduced in the main areas where the pathological changes occur and its expression levels reflect the progression of the disease (Duan et al., 2008). CX3CL1 is also decreased in the cerebrospinal fluid of patients with Alzheimer’s disease, and patients with mild to moderate Alzheimer’s disease have significantly higher plasma CX3CL1 levels compared to patients with the severe form of the disease (Kim et al., 2008; Perea et al., 2018b). In APPPS1 mice, an Alzheimer’s disease study model, CX3CR1 knockout showed a reduction in Aβ deposition and fewer CD68 positive microglial cells (Lee et al., 2010). Furthermore, CX3CR1 deficiency reduced the number of microglia surrounding Aβ deposits in a dose-dependent manner of with levels of CX3CR1 gene expression (Lee et al., 2010). The impairment of CX3CL1-CX3CR1 signaling, which mainly impacts the functional signaling of microglia, seems to be a central point between inflammageing and the development of neurodegenerative diseases.

The relationship between infection and neurodegenerative diseases could be subtle and may rely on microglial priming. Infections, even non-neurotropic ones, may lead to an inflammatory condition in the brain mainly mediated by the pro-inflammatory microglial state. The inflammatory response caused by infections has been associated with microglial priming events that may induce changes in their state and function. Despite priming events that prepare microglial cells for subsequent immune challenges to promote repair and homeostasis, microglia are long-lived cells that are constantly exposed to infections during an individual’s lifetime, and this also may not be beneficial, as it may contribute indirectly to neurodegenerative disorders.

All authors made substantial contributions and participated in drafting the article and revising it critically. All authors contributed to the article and approved the submitted version.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.